Location [1]
Protein [2]
Synonyms [1]
NT5, eNT, CALJA, NTE, CD73, NT, eN, E5NT

NT5E is altered in 0.74% of all cancers with breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

NT5E GENIE Cases - Top Diseases

The most common alterations in NT5E are NT5E Amplification (0.03%) and NT5E Loss (0.01%) [3].

NT5E GENIE Cases - Top Alterations

Significance of NT5E in Diseases

Fallopian Tube Carcinoma +

Fallopian Tube Carcinosarcoma +

Fallopian Tube Endometrioid Adenocarcinoma +

Fallopian Tube Undifferentiated Carcinoma +

High Grade Fallopian Tube Serous Adenocarcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Malignant Ovarian Mixed Epithelial Tumor +

Malignant Ovarian Neoplasm +

Malignant Peritoneal Neoplasm +

Ovarian Carcinoma +

Ovarian Carcinosarcoma +

Ovarian Endometrioid Tumor +

Primary Peritoneal Carcinosarcoma +

Primary Peritoneal Endometrioid Adenocarcinoma +

Primary Peritoneal Serous Adenocarcinoma +

Primary Peritoneal Undifferentiated Carcinoma +

Undifferentiated Ovarian Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.